Universal Health Services, Inc. UHS
Composite 59/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 33/100 — a moderate mark against it.
Valuation ranks 74/100 — a moderate point in its favour. Quality ranks 64/100 — a moderate point in its favour. Balance-sheet strength ranks 62/100 — a moderate point in its favour.
Momentum ranks 33/100 — a moderate mark against it. Income ranks 37/100 — a moderate mark against it.
What the company does Universal Health Services, Inc. (UHS) operates acute care hospitals and behavioral health facilities across the U.S., offering surgery, emergency care, oncology, and behavioral health services. It also provides insurance, capital resources, and management services to affiliated facilities.
Key financials UHS reports strong profitability metrics: ROE 20.9%, ROA 8.3%, and ROCE 17.2%. Gross, operating, and net margins stand at 44.6%, 11.1%, and 8.4%, respectively. Revenue grew 9.7% while EPS surged 36.9%, supported by a Piotroski F-Score of 7/9 and Altman Z of 3.08.
Stock health Sideravia scores UHS 59.0 overall, citing average quality but weak momentum (30.7). The stock shows mixed performance: +3.68% over 3 months but -26.59% over 6 months. Debt metrics are moderate (Debt/Equity 0.69, Interest coverage 13.99), with a current ratio of 1.12.
Price vs fair value The stock trades at a **discount of 12.50%** to the analyst mean target of 193.94. - UHS closed an $835M Talkspace acquisition to expand virtual behavioral health (Healthcare Dive). - Analysts highlight competitive advantages in a challenged sector (StockStory). - Recent Q2 updates and growth initiatives may support long-term value (StockStory, Zacks).
Looking forward Forward P/E of 7.41 and EV/EBITDA of 5.38 suggest valuation appeal, though momentum remains weak. Growth in behavioral health and operational efficiency could drive future performance. Dividend yield is low at 0.5%.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.